🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Data and Global Access

As per findings detailed in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The trial included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians on the front lines have shared positive views. Having a one-pill regimen such as this is hailed as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.